Related Experiment Video
Updated: Aug 9, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Evaluation of chemosensitivity of human bone marrow stromal cells--differences between common chemotherapeutic drugs
Ralf Schmidmaier1, Philipp Baumann, Bertold Emmerich
1Department of Hematology and Oncology, Medizinische Klinik Innenstadt, Klinikum der Universität München, Munich, Germany. ralf.schmidmaier@med.uni-muenchen.de
Background:
Bone marrow stromal cells (BMSCs) are essential for normal hematopoiesis, but also support the growth and survival of malignant hematopoietic cells. There are currently no data available regarding the sensitivity of BMSCs to cytotoxic drugs widely used in the therapy of hematological diseases such as multiple myeloma or acute leukemia.
Materials And Methods:
The chemosensitivity of the BMSC line HS-5 and of primary BMSCs from patients were evaluated in comparison to NCI-H929 myeloma and U937 leukemia cells.
Results:
Both HS-5 cells and human BMSCs showed substantial cell death in response to chemotherapy. While alkylating agents (melphalan, treosulfan) and doxorubicin demonstrated marked BMSC toxicity, nucleotide analogs (gemcitabine, cytarabine) induced only limited BMSC apoptosis.
Conclusion:
Our data suggest that the BMSC toxicity of cytotoxic compounds should be considered in chemotherapeutic regimens.

